1. Prospectus by Tom Grahn
on DEA for US interested
parties , November 2015
•Clinical Epigenetics Journal 2015, 7:33
Tom Grahn, Finland, +358 500 828486, tpgrahn@gmail.com
18.11.2015 1

2. 18.11.2015 2

3. 18.11.2015 3

4. 18.11.2015 4

5. 18.11.2015 5

6. HCYSAHH
PC ~
PE
SAH
SAM
CARDIOVASCULAR
IMPACT &
ANTIATHEROGENIC
ANTIATHEROSCLEROTIC
COGNITIVE
IMPROVEMENTS
EPIGENETIC
METHYLATION
STATE CONTROL
ENHANCED MEMBRANE FLUIDITY
ω3 BOOSTING
18:2
18:3
CATABOLISMVia SREBP 1
Δ6D
+CH3
-CH3
Tom Grahn All rights reserved +358 500 828486 tpgrahn@gmail.com Finland Nov 2015
USE OF DEA
GLOBALLY
PROTECTED
DEA
human
daily dose
30 mg
Phospholipidic
modification !
18.11.2015 6

7.  DEA is a phosphilipidic modifier and down-
regulates PC/PE. This in turn deactivates
SREBP 1 ( Yewon Cheon Dr Thesis 2008 )
which is a key catalyser in fatty acid
metabolism. Via the SREBP 1 the D6D ( delta-
6desaturase ) anabolism is inhibited and w3
boosted. SAHH is kinetically reducing HCY.
The One Carbon Ring rotation is regulated by
the +CH3/-CH3 state of SAH/SAM. DEA is
epigenetic “ medicine “The multitherapeutic
window of DEA is governed by these facts
18.11.2015 7

8.  * DEA was discovered in Japan in 1966 and Tanabe and
Fujisawa was fiercely competing for 10 years.
 * DEA as a potent SAH hydrolas inhibitor was discovered
in 1982 by Vortruba and Holy
 * The Sugiayama theorem goes back to early 1990’s: ”
PC/PE reducers are always hypocholestermic ”
 * Dr Shimada revealed the sequential nutrition kinetics of
DEA over PC/PE and fatty acid catabolism in 2003
 * Dr Cheon 2008: ”SREBP 1 is the transcriptional regulator
and its activity is regulated by membrane PC/PE ratio”
 * It is only recently the understanding of epigenetics and
nutrition versus state of methylation is paying off.
 * All this, and more, is included in this S&T platform
18.11.2015 8

9. DEASC
DEASC stands for
DEA supply chain
•A fermentation
manual was
performed in 2010
• Separation of DEA
is performed by
HPLC since 2011
• For pharma
purposes DEA can
be synthetisized
18.11.2015 9

10. 18.11.2015 10

11. Taken together, these 10 pages offer clearly
the following therapeutic window:
1. Hypocholesteremic due to PC/PE, SREBP1
and D6D
2. Hypohomocysteinemic due to SAHH inhibition
an kinetic fact
3. EFA boosting and membrane fluidity
due to D6D inhibition
4. Epigenetic control due to SAM/SAH
regulation
5. Vascular cognitive effects due to the above four
18.11.2015 11

12.  D-eritadenine is
 FOSHU in Japan
 GRAS in the USA
 Novel Food in Europe
 EFSA biomarkers are( European Food Safety Authority)
 LDL and HDL
 HCY
 Blood pressure and platelet activity
 DEA impacts all these and is multitherapeutic in
pharmafood sence
18.11.2015 12

13. US PATENTS
USA, 9.11 2004 USP
6,814,975 B1 24.11 2000
Granted
Exp 19.3 2021
USA, 27.6 2006 USP
7,067,146 24.11 2000
Granted
Exp 20.11 2020
The patents are maintained and
owned by EritoCap Ltd, the Grahn
company
18.11.2015 13

14. All this is …
Available through my
company EritoCap Ltd,
FI 1469575-5 Finland,
trade registered 734.081,
domicile Turku, Finland.
Tom Grahn:
I sell all and
participate in
commercialisati
on at face cost of
15 yrs of work.
18.11.2015 14